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 Abstract 
  Background/Aims:     At our hemodialysis (HD) unit, we noted a drop in the treatment dose of 
erythropoietin-stimulating agents (ESAs) when the frequency of dose adjustment was reduced 
from weekly, where doses were withheld if hemoglobin was   1  130 g/l, to monthly, where doses 
were not withheld. The aim of this study was to find an explanation for this reduction in ESA 
requirement.   Methods:   This is a retrospective study on 18 stable HD patients. Comparable fol-
low-up periods of 6 months with the two different ESA adjustment regimens were established 
and data on ESA dose, hemoglobin and known predictors of ESA response were collected.
  Results:  With the new ESA administration regimen, a 22.5% drop in the total ESA dose was not-
ed. The corresponding fall in the erythropoietin resistance index was 20.0%. Simultaneously, 
the dialysis dose and transferrin saturation increased significantly. However, in a multivariate 
linear regression model, changes in these factors did not significantly predict changes in ESA 
requirement. No relevant changes were noted in other erythropoiesis-modulating factors.  Con-
clusion:  Frequent dose adjustments and the current ESA administration practice of withholding 
ESA doses does not seem to reduce ESA demand. On the contrary, such practice is likely to in-
crease ESA requirement over time.    Copyright © 2011 S. Karger AG, Basel 
  Published online: August 19, 2011 
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 Introduction 
  In chronic renal failure, anemia is generally believed to result from insufficient produc-
tion of erythropoietin by the diseased kidneys   [1]  . However, the etiology is much more com-
plex: many anemic patients have serum erythropoietin levels within the reference interval 
 [2, 3]  and numerous factors can affect erythropoiesis, such as iron deficiency, inflammation, 
infection, uremic toxins, malnutrition and hyperparathyroidism   [4]  .
    The core treatment of renal anemia is to stimulate erythropoiesis by regular injections 
with erythropoiesis-stimulating agents (ESAs), such as recombinant human erythropoietin 
  [5]  . This treatment is expensive and constitutes a substantial part of the dialysis patients’ to-
tal health care costs   [6]  . According to international guidelines, the optimal hemoglobin lev-
el in patients with end-stage renal disease is 110–120 g/l   [5, 7]  . It is not easy to maintain he-
moglobin within these tight limits, and ESA doses are adjusted frequently.
  In our hemodialysis (HD) unit, hemoglobin levels have been measured weekly for many 
years and the ESA dose was withheld if the hemoglobin value was   1  130 g/l. On the basis of 
the observed large fluctuations in week-to-week hemoglobin values as well as the possibility 
of neocytolysis  [8]  and erythroid progenitor apoptosis when ESA treatment is withdrawn  [9] , 
we decided to change this practice. From November 1, 2007, hemoglobin measurements and 
ESA dose adjustments were performed monthly instead of weekly. Moreover, the ESA dose 
was withheld only if the hemoglobin value was   1  140 g/l. After this change in ESA adminis-
tration, we experienced an approximately 20% reduction in the total ESA supplementation. 
The aim of this study was to evaluate if the change in the ESA administration practice could 
explain the reduction in the ESA demand.
  Patients  and  Methods 
  Patients and Study Design 
  We conducted a retrospective analysis on data from our Renal Unit at the Sahlgrenska 
University Hospital, Mölndal, Sweden. The main demographic and clinical characteristics 
of the study subjects are summarized in   table 1  .
   Figure 1  shows an algorithm denoting the screening and inclusion/exclusion details. All 
patients on chronic HD treatment on November 1, 2007, were screened for participation in 
the study. At this date, our routines regarding the administration of ESA were changed 
(change point). Patients meeting the inclusion criteria had been on HD for at least 3 months 
prior to the study start. They were also treated regularly with subcutaneous ESA injections. 
Among eligible subjects, we carefully selected patients to create a subpopulation allowing 
analysis of intra-individual changes in ESA requirement. For each patient, comparable peri-
ods of equal duration (6 months) before and after the change point were selected (periods 1 
and 2, respectively).
    The patients had to be in clinically stable condition and were excluded if any of the fol-
lowing criteria occurred within 8 months before or within 7 months after the change point; 
acute inflammation/infection with C-reactive protein (CRP)   1  150 mg/l at any time or CRP 
  1  100 mg/l for   1  2 days, acute operation, blood transfusion, acute cardiovascular event (acute 
myocardial infarction or stroke) or diagnosis of cancer. Moreover, we excluded patients if the 
rate of HD per week was higher after the change point. After applying the exclusion criteria, 
data from 18 patients were collected and analyzed.47
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    Change in the ESA Administration Regimen 
  On November 1, 2007, we changed our erythropoietin administration regimen. Before 
that day, hemoglobin measurements and ESA dose adjustments were performed weekly. 
Capillary hemoglobin was measured before dialysis and if it was   1  130 g/l the dialysis nurse 
automatically withheld the ESA dose. The following week, ESA was restarted with a lower 
dose if the hemoglobin value had dropped   !  120 g/l; otherwise it was withheld for another 
week. Subsequently, we changed this practice. For all patients, the prescription of ESA was 
altered. The new dose was based on the previous mean delivered ESA dose over time, calcu-
Patients, n 18
Females/males 7/11
Age, years 66.6812.5
Causes of renal failure, n
Unknown 6
Diabetic nephropathy 4
Chronic glomerulonephritis 1
Chronic interstitial nephritis 3
Nephrosclerosis 1
Other 3
Time on current HD treatment, months 41.1832.1
Dry weight, kg 77.7815.5
Serum levels
Creatinine, mol/l 7738182
Urea, mmol/l 24.686.2
Calcium, mmol/l 2.2380.11
Phosphate, mmol/l 1.880.5
Bicarbonate, mmol/l 22.981.3
Table 1.   The main demographic 
and clinical characteristics of 
the study subjects
  Fig. 1.   Screening and inclusion/
exclusion details of all patients 
on chronic hemodialysis (HD) 
on November 1, 2007, for partici-
pation in the study. At this date, 
our routines regarding ESA
ad  ministration were changed 
(change point). Patients meeting 
the inclusion criteria had been 
on hemodialysis for at least 3 
months prior to the study start. 48
Nephron Extra 2011;1:45–54
 DOI:  10.1159/000329889 
EXTRA
  Stefánsson et al.: Reducing ESA Supplementation 
www.karger.com/nne
    © 2011 S. Karger AG, Basel
  Published online: August 19, 2011 
lated as total ESA dose administered per week for the previous 12 months or from the start 
of dialysis. In all cases, this dose was lower than the prescribed one because of the ‘withhold-
dose’ practice. No capillary hemoglobin measurements were performed, and the ESA dose 
was instead adjusted to monthly hemoglobin measurements performed at our local clinical 
laboratory. The dose was adjusted if hemoglobin was  1 120 or  ! 110 g/l, and the dose was only 
withheld if hemoglobin exceeded 140 g/l. In all cases, ESA dose adjustments were performed 
according to the physicians’ judgment.
    Dialysis Treatment and Blood Sampling 
  For each patient, the dialysis modality was the same in both periods. No patient was 
treated with hemodiafiltration or hemofiltration. At the change point, the method applied 
to measure the dialysis dose was changed from single-pool Kt/V (spKt/V), with urea mea-
sured 2 min after dialysis, to equilibrated Kt/V (eKt/V) with urea measured immediately 
after dialysis   [10]  . As these two methods do not give comparable results, dialysis dose was 
calculated as dialyzed blood volume per kilogram per dialysis session. Arteriovenous (AV) 
fistula recirculation was evaluated every month using Transonic flow surveillance.
    At the change point, we also altered our practice regarding monthly blood sample col-
lection. Blood was now collected before the start of the midweek dialysis session (2 days after 
the previous dialysis) instead of the first dialysis session in the week (3 days after). All the 
above-described changes were done to adapt our routines to international guidelines  [11]  and 
the National Hemodialysis Cross-Sectional Study performed twice a year throughout the 
country by the Swedish Dialysis Data Base.
    Data Collection, Calculations and Statistical Analyses 
  The original intention was to collect data from each patient for 12 months in each pe-
riod. However, only 10 patients were stable and eligible for the study over such a long time. 
Instead, data from 6 months in each period were collected. As the ESA dose was fixed dur-
ing the 1st month after the change point, this month, as well as the month before the change 
point was excluded.
    Monthly routine clinical laboratory analyses from our local dialysis database were col-
lected. From the same database, information of potential blood transfusions, dialysis dose 
and iron/erythropoietin supplementation were assessed.
    The time point for monthly blood collection was changed between periods 1 and 2, but 
this was compensated for by calculating a corrected hemoglobin value after dialysis from the 
linear relationship between the hemoglobin value before dialysis and the respective intra-
dialytic body weight loss   [12]  . Thus, hemoglobin values in periods 1 and 2 were rendered 
comparable and these values were then used to calculate the erythropoietin resistance index 
(ERI): ERI = ESA dose (IU/week)/weight (kg)/hemoglobin value (g/dl), where IU is the ab-
breviation for international units.
    Microsoft Excel software was used to register data and generate graphs. Data are pre-
sented as means or medians   8   SD. Statistical analyses were performed with the software 
package SPSS. Because of the small study cohort, non-parametric tests (Wilcoxon and Krus-
kal-Wallis tests) were regarded as appropriate to compare means. Spearman’s correlation (   ) 
was used to study bivariate associations, and a univariate linear regression model was used 
in multiple regression analyses.49
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  R e s u l t s  
  Hemoglobin, ESA Supplementation and ESA Resistance 
  Sixteen patients received weekly subcutaneous epoetin      injections (NeoRecormon; 
Roche) and 2 patients were treated with intravenous darbepoetin      (Aranesp; Amgen) ev-
ery other week. Both of these patients were switched to epoetin      during period 2. The dose 
of darbepoetin      was multiplied with 200 to convert from micrograms into IU.
      Figure 2   illustrates month-to-month variation in total ESA supplementation per week 
and hemoglobin levels before dialysis during the entire follow-up time. The range of ESA 
doses prescribed was 4,000–30,000 IU per week in period 1 and 2,000–30,000 IU per week 
in period 2. The mean ESA dose levels, the ERI and hemoglobin values during the respective 
periods are shown in   table 2  . The magnitudes of all these parameters were lower in period 2, 
albeit being only significant for ESA dose and ERI. The reduction was 22.5% for the mean 
ESA dose per week, 19.9% for ERI, 0.9% for hemoglobin before and 1.9% for hemoglobin af-
ter dialysis. The mean reductions in the ESA dose per week and ERI were –4,015   8  3,633 IU 
and –3.0   8   4.3 IU/week per kg per g/dl, respectively.
    Predictors of ESA Response 
    Table 3   shows mean levels of well-known predictors of ESA response in each period. Se-
rum transferrin saturation and dialyzed blood volume were significantly increased in period 
2. Further, together with serum ferritin, these parameters were significantly negatively corre-
lated to changes in ERI (  table 4  ). However, in an adjusted model where serum ferritin and 
transferrin saturation were omitted due to bidirectional effects with the outcome variable, di-
alysis dose was not a significant independent predictor of change in ERI (  table 5  ). The mean 
dialysis dose measured by Kt/V was 1.46  8  0.23 (spKt/V) in period 1 and 1.41  8  0.21 (eKt/V) 
in period 2. No further statistical analyses were performed as these two parameters are not 
equivalent. In patients with an AV fistula, no recirculation was observed during the follow-up.
    There was a significant difference between periods 1 and 2 regarding the time that had 
passed from intravenous iron injection to the analysis of iron parameters. Thus, in period 1, 
64 of 108 blood samples were collected within 3 weeks (mean 10.3 days), compared to 70 of 
  Fig. 2.   Month-to-month variation in total ESA supplementation per week and hemoglobin levels before 
dialysis during the entire follow-up. 50
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Table 2.   Erythropoiesis parameters during both periods (means 8 SD)
Parameters Period 1 Period 2 p value
Hemoglobin, g/l
Before dialysis 117.084.8 115.985.1 NS
After dialysisa 125.184.7 122.785.4 NS
Intravenous iron treatment, mg/day 5.184.5 5.083.9 NS
ESA dose, IU/kg/week 186.58117.8 144.68126.4 <0.01
ERI, IU/kg/week per g/dl 15.189.9 12.1811.0 <0.01
a  Estimated hemoglobin according to Bellizzi et al. [12].
Table 3.   Mean levels of well-known predictors of ESA response in both periods (means 8 SD)
Predictors Period 1 Period 2 p value
Dialysis sessions, n  76.882.7 75.986.4 NS
Dialyzed blood volume, l/kg/session 0.9080.20 0.9880.18 <0.01
Serum transferrin saturation, % 22.285.1 27.689.4 <0.05
Serum ferritin, g/l 4708189 5288243 NS
Serum CRP, mg/l 9.987.2 12.6811.1 NS
Serum albumin, g/l 35.882.2 36.283.5 NS
Serum PTH, ng/l 4198384 3538210 NS
Predictors rs p value
Changes in
Dialyzed blood volume –0.55 0.017 
Serum transferrin saturation
Serum ferritin
Serum CRP
Serum albumin
–0.55
–0.48
0.44
0.00
0.018
0.042
0.065
1.000
Serum PTH –0.19 0.453
Predictors  95% CI  p value
Changes in
Dialyzed blood 
volume –17.44 –40.71 to 5.84 0.130
Serum CRP 0.037 –0.34 to 0.42 0.838
Serum albumin 0.015 –1.13 to 1.16 0.979
Serum PTH 0.001 –0.01 to 0.01 0.712
T  ransferrin saturation and ferritin were omitted from the model 
because they are modified by ESA.
Table 4.   Spearman’s correlation 
() between changes in 
predictors of erythropoiesis and 
changes in ERI
Table 5.   Results of a multiple 
linear regression model with 
ERI as outcome and changes in 
factors influencing 
erythropoiesis as predictors51
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107 (mean 6.9 days) in period 2 (p   !   0.001). Further, in period 1, all samples were collected 
  1  3 days after the intravenous iron injection, while in period 2, 26 samples were drawn with-
in 3 days (6 patients). In these 6 patients, serum ferritin and transferrin saturation increased 
significantly in period 2 (+224   8   89     g/l and +12.3   8   6.1%, respectively; p = 0.028 in both 
cases). On the other hand, this was not seen in the other 12 patients where all samples were 
collected  1 3 days after intravenous iron injection. Here, the changes from period 1 to period 
2 in serum ferritin levels and serum transferrin saturation were –25.4   8   281    g/l  and
+1.9   8   8.0%, respectively (nonsignificant).
    Sixteen patients were treated with intravenous iron injections, 2 of them only in period 
1 and 2 patients only in period 2. Mostly iron sucrose (Venofer  ; 100 mg/injection) was used 
in period 1 (157/169 doses) while iron dextran (Cosmofer  ; 50 or 100 mg/injection) was more 
frequently used in period 2 (115/174 doses). The total intravenous iron supplementation did 
not differ between periods 1 and 2 (16.7 and 16.5 g, respectively). To analyze the possible re-
lationship between changes in iron dose and changes in ERI, we divided the patients into two 
groups: A (more intravenous iron in period 2, n = 6) and B (less or equal intravenous iron in 
period 2, n = 12). The reduction in ERI was larger in group B than in group A (–3.4  8  3.1 vs. 
–2.1   8   6.4 IU/week/kg per g/dl, respectively). However, this difference was not statistically 
significant (p = 0.553).
    At the start of follow-up, 7 patients had an AV fistula and 11 had permanent central
dialysis catheters (CDK). During the follow-up, 6 patients had their dialysis access changed 
from CDK to AV fistula. The mean     ERI for these 6 patients was –4.5   8   3.7, compared to 
–0.6  8  4.0 and –4.6  8  4.6 for patients with AV fistula and CDK, respectively. The difference 
between the groups was not statistically significant.
    Predictors of Hemoglobin Concentration 
  In a bivariate Spearman’s correlation analysis (    ), changes in transferrin saturation and 
serum ferritin were significantly correlated with changes in hemoglobin after dialysis (p = 
0.02 and 0.04), while changes in ESA dose per week were not significant. In a multiple regres-
sion analysis, with changes in hemoglobin after dialysis as outcome and changes in transfer-
rin saturation, dialyzed blood volume, CRP, serum albumin and parathyroid hormone 
(PTH) as predictors, only transferrin saturation turned out as an independent predictor
(     = 0.414, p = 0.019).
  Discussion 
  The aim of this retrospective study was to find out if it is a reasonable assumption that 
a new ESA administration regimen with fewer dose adjustments and fewer withheld doses 
could explain a 22% drop in total ESA supplementation. Such an assumption can only be 
made by ruling out other possible explanations, such as changes in factors that are known to 
affect erythropoiesis. We systematically evaluated these factors and found two other poten-
tial explanations; increased dialysis dose and higher transferrin saturation. However, as dis-
cussed below, in our opinion, the drop in ESA requirement  is most likely due to the new ESA 
administration routine.
  In patients with chronic renal failure, the hematocrit response to ESA is dose dependent 
  [13]   but dose variation is huge, both between individuals   [14]   and within a given individual 
  [15]  . In consequence, frequent dose adjustments are required to keep the hemoglobin value 
within the recommended interval   [16]  , i.e. between 110 and 120 g/l in patients on chronic 
HD   [5, 7]  . In our study, the mean hemoglobin level before dialysis was within this range and 
ESA requirement was comparable to that reported by others   [17]  .52
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    Numerous factors can affect the ESA response   [4]  , e.g. inflammation and infection   [18, 
19]  , iron deficiency   [20]  , malnutrition   [21]   and dialysis dose   [22]  . This study was designed to 
minimize the influence of these factors by creating comparable individual study periods be-
fore and after the change point. Periods with severe acute infection or inflammation were 
excluded. However, the mean serum CRP level was higher in period 2, although the differ-
ence was not significant. In fact, this excludes this factor as explanation for lower ERI in pe-
riod 2. All patients were iron replete and, as the overall iron supplementation was similar in 
both periods, we can reject intravenous iron treatment as explanation for the decrease in ESA 
requirement. However, surprisingly, serum transferrin saturation was significantly higher in 
period 2. If true, this could explain a lower ERI, because changes in transferrin saturation 
predicted changes in hemoglobin. Therefore, what is the explanation for the enhanced satu-
ration? Most likely, it is due to the shorter interval between intravenous iron injection and 
measurement of iron parameters in period 2, but other reasons are also possible. In period 
2, more patients were treated with iron dextran and, as it has a longer half-life   [23]   than iron 
sucrose, the intravenous iron agent mainly used in period 1, this may explain the longer-
lasting elevation in serum iron parameters after the injection. Further, withholding ESA 
doses in period 1 can affect iron homeostasis in various ways through factors like neocy-
tolysis (see below), iron utilization and hepcidin.
  The changes in serum ferritin were not correlated to the changes in CRP, indicating that 
the rise in ferritin did not reflect inflammation. Not surprisingly, changes in ferritin were 
negatively related to changes in ERI (  table 4  ), a finding simply reflecting higher iron utiliza-
tion when ESA dose is increased.
    Serum albumin is a strong predictor of ERI   [24]   and a marker of inflammation   [25]   and 
malnutrition   [26]  . The albumin level was slightly, but not significantly, higher in period 2. 
On the other hand, changes in albumin were not correlated to changes in ERI ( table 4 ), which 
speaks against an improved nutritional status as part of the explanation.
    An inverse correlation has been described between the adequacy of dialysis (measured 
by Kt/V) and changes in ERI   [22]  . Unfortunately, the change from spKt/V to eKt/V at the 
change point made comparison of this parameter impossible. Instead, the dialysis dose was 
measured by dialyzed blood volume per kg body weight per dialysis session. As demonstrat-
ed in   table 4  , a change in dialysis dose was negatively correlated with changes in ERI, but it 
was not a significant independent predictor of ERI in a multiple regression model (  table 5  ). 
However, there is a possibility of a type-2 error here, as the confidence interval for    was wide 
and predominantly negative. In this case, an increase in the dialysis dose could explain a de-
crease in ESA need. If true, this is in contrast to previous studies in patients on HD thrice 
weekly, reporting that the beneficial effect of dialysis dose on erythropoiesis vanishes at
Kt/V   1   1.3   [27, 28]  .
    Concomitant with the change in ESA administration practice, the monthly blood col-
lection was rescheduled from the 1st to the 2nd dialysis session in the week   [12]  . In theory, 
HD patients without adequate urine production gain less weight with shorter inter-dialysis 
periods which results in higher hemoglobin values and, consequently, downward adjustment 
of the ESA dose. Indeed, this could be part of the explanation for the decreased ESA use in 
period 2. Arguing against this is that we did not note any increase in hemoglobin before di-
alysis after the change point. On the contrary, the mean hemoglobin value before dialysis 
was lower in the month succeeding (116.6  8  7.6 g/l) than in the month preceding the change 
point (118.4   8   8.9; p = 0.285).
    One could argue that the reduced ESA demand is explained simply by the fall in the he-
moglobin value. Indeed, simultaneously with the drop in ESA dose by 4,015 IU per week, 
hemoglobin levels before and after HD fell by 1.1 and 2.4 g/l respectively. However, changes 
in hemoglobin were not correlated to changes in ESA dose.53
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    Taken together, the reason for the lower ESA requirement after the change point is not 
clear. For many years, we believed that we could reduce ESA costs by withholding doses if 
the hemoglobin value was  1 130 g/l. There is a possibility of neocytolysis when ESA doses are 
withheld. This is a normal physiological mechanism where the body rapidly adapts to inap-
propriately high levels of red cell mass by promptly decreasing the erythropoietin production 
  [29]  . In turn, young erythrocytes are rapidly removed from the circulation by hemolysis in 
the spleen. Indeed, it has been postulated that neocytolysis can contribute to anemia in HD 
patients when EPO doses are withheld   [8]  . There is another potential consequence of with-
holding the ESA dose in an ESA-dependent patient: As erythropoietin prevents apoptotic 
death of erythroid precursor cells   [30, 31]  , a sudden drop in erythropoietin concentration 
can result in a more pronounced loss of these cells.
    The major limitation of this study is that it is small and observational. Optimally, our 
results should be confirmed by prospective randomized trials that can give us answers to the 
following questions evoked by our work: Does neocytolysis occur when ESA doses are with-
held? Is there any difference between iron sucrose and iron dextran regarding transferrin 
saturation over time and response to ESA? Can we reduce ESA need by increasing dialysis 
dose in patients already receiving an adequate dialysis dose (Kt/V   1   1.3)? Still, it is fair to 
conclude that the ESA administration praxis where ESA doses are withheld does not reduce 
ESA demand. Instead, such practice could be associated with higher ESA requirements over 
time. On the basis of our results we recommend monthly rather than weekly hemoglobin 
measurements and a decrease in ESA dose rather than discontinuation of ESA treatment 
when an adjustment of hemoglobin treatment is considered necessary.
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